Announcements Trials
Browse Landscape

Phase

Phase NA 8Phase 1 2Phase EARLY_PHASE1 1Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 1Dermatologic 1CNS 1

Conditions

Neuroblastoma 1Basal Cell Carcinoma of the Head and Neck 1

Interventions

Cyclophosphamide 624pembrolizumab 500Paclitaxel 456Gemcitabine 438Carboplatin 435Cisplatin 418Radiotherapy 380fludarabine 365Nivolumab 340Docetaxel 277Bevacizumab 276Irinotecan 257Magnetic Resonance Spectroscopy 242Fluorouracil 228Dexamethasone 225Specimen Handling 221Capecitabine 218Rituximab 205Cytarabine 201Oxaliplatin 200Ipilimumab 199Temozolomide 197Biopsy 196fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 173Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Interventional × Tissue Banks × Clear all
NCT04323202 2025-10-24

Neoadjuvant-Adjuvant Pembrolizumab in Resectable Advanced Basal Cell Carcinoma of H&N

Case Comprehensive Cancer Center

Phase 1 Completed
13 enrolled
DermatologicHead & Neck

Basal Cell Carcinoma of the Head and Neck

NCT04239040 2025-03-19

GVAX Plus Checkpoint Blockade in Neuroblastoma

Dana-Farber Cancer Institute

Phase 1 Terminated
19 enrolled
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡